and safe us staying Chris. Okay. hope Thank unique you joining families times. thank I for you, your healthy are Good you today. afternoon and and during these
and research we're I we've performance advance operating we stay supporting core our how update The to Before best doing serve at the forward. we and current to this in on talk rapidly Glaukos of our to customers priorities learned an changing our our response our trends environment what business, advance to we've want the response second-quarter been prioritized going and in lessons months, key projects provide the key health applying preserving past their strong over families, including of pandemic, our maintaining focused position the and strategic and financial safety to and and us a customers, globally, development jobs several protecting employees priorities. following have and our plans the allowed implemented and protecting and
and glaucoma, and the employees strong who the franchises our resourcefulness capable recognize to As around result. corneal I we company positioned of disruptive even more fundamental more a and are foundation remain the dedication as prospects disease. a and retinal up well our the world strong emerge our make efficient result, and of stronger, underlying resiliency, health to in the want
also exemplifies our their employees operating the new new was company successfully the maintain through of during step gratitude This an express ophthalmic Glaukos. the committed creativity, to who to important work example implementation world their their hard treatment work virtual of went unique in serving the was a interventions, during We work achievement effective to safety quarter. and beyond safe clear Its in future alongside and important while ensure our for this families returning times. many follow our and above and patients. an the for that shall risen have around them. ongoing X we dedicated a pandemic. sacrifice entire the and customers company, practices our to essential ERP preparation for creative the growth, and move enhanced across Tier to up measures forward. throughout to adapting employees their moment Our are effort these successful organization our while and to of in providers the remain I environment ways One want system second live Thanks during their on Oracle the communities patients
re-engage with engagement webinars ophthalmic our virtual they will this complementary we're surgeons our as mind, and person, ongoing [indiscernible] in doctors by are designed have many While customer-oriented professionals encouraged this of navigate in well-respected that customers to invested field-based of hosted practices endure. accounts With the crisis. support in sales physicians we to
and held assure and efforts have protocols through modules, help COVID-XX. case-based platforms train We peer-to-peer We've new procedure to interactive clinical using variety remote with other confident calls, customer expanded of of practices have various regional and I'm based support use to training virtual ophthalmic programs. new collaborate on optimal have these proctor our with that identified training surgeons tutorials prepare programs us deepen conference relationships the beyond meetings investigator and online virtual compliance ongoing where developed education a future ensure applicable. clinical customer and to virtual efforts enrollment and virtual opportunities trial cases platforms patient to implemented provide to manage resources help ongoing drive virtually the digital We've that for well many valuable helped educational numerous settings. and outcomes, and cases proficiency we
manufacturing order to that to in our our period, pleased date. to sites experienced processes chains and through product we minimal main consistently during have During supply and albeit have to this this operate am operational disruption of provide us. on depend customers time, continued both who also assembly maintained differently our to resiliency streamlined I say
highly levels Moving to the were second rate sales cataract challenges the the call, trends our increasing details in the as prior care by trends approximately with want COVID-XX discipline Troughed world. and health sales the and we XX% international on month-to-month second was COVID-XX are and the government the and $XX.X million across corneal to US the trends the minutes in call, in run global throughout health we that franchises, within to led but later the a exited XX% to for how the June Despite our of few the These XXXX restart the sales sales as potential last Joe were of financial May net dependent procedures. and the deferral mid-April therapies implemented opportunity a increase experienced restrictions markets provide quarter on the were virus shifted to and restrictions were disruptions reflecting and an to by discussed surprisingly, near-term reopen remainder our resources our procedures states I financial over and in this impact outbreak. organization keratoconus additional that our and geographies. the averages. US procedures that in the see second-quarter a variety market on performance. recovery quarter Glaukos. we with and spend key trends to of to recovery of global and glaucoma, spending sales, revenue material in elective Not itself of treatment These of quarter Net glaucoma business encouraged continue on dynamics see to pleased scenarios pandemic and associated during providers we pre-COVID our elective our on exhibited in and began at ongoing began by approximately achieved material to system will
elective cancellations during is continue the closure home local the and matter. note worst While that many is procedures considerations behind of of mandates it facilities. in could and temporary that be of dynamics monitoring market of majority The the and spikes these to at level shelter to we to us increase an that surgery government important scenarios, patients are the recovery ongoing for regardless lead in several vast and achieved downstream is impacted pandemic to lead even can result absolute by closely. scheduled Resurgence also
diagnosing ophthalmologists First, visits cataracts, glaucoma optometrists to primary to keratoconus. and key are care and
demand headwinds may are vision New persist primary patient care delayed visits deferred. or as
faster a headwind distancing procedural surgery you modest than office are across enhanced efficiency be sustainability of of might operating center and seeing protocols. the site site other sites and procedures But physician Secondly, the service, social average. impacted ambulatory by procedures hospital-based and a can create recovering safety expect. In all settings general, at we on restrictions the as volumes clip
As a technologies in in centers. surgery primarily the surgeries, our our outpatient solution United the XX% reminder, of for office. physician's in keratoconus estimated of in which are ambulatory all be States is used And to performed are glaucoma Photrexa performed
doctor Whilst the and on with is as ability Third, commercial our the to again organization corneal trends glaucoma a new pleased training the weeks, deliver health. our key have market in fronts. recent is costs in we of starts to franchise new element Photrexa grow all in been our exist, beginning
diseases to place. keratoconus continue end the multiple left certain worsen our cataract recent not normalized a dynamics and in only COVID-XX As headwinds XXXX is the here you remainder a foundation our the modest may day, of together, levels that chronic all But solutions materialize we has months. tailwinds setting patients ophthalmic only these of am COVID-related drive strengthened expect are address vaccine aside, commercialized solution therapeutic from will the over into or untreated. as put more in this until and I that for that procedures At recovery ultimately
me, we Most deferred medical in specific performed timing pandemic remain the subsides, difficult predict recovery the to of future necessity be and the is procedures the for interventions, ultimately the as slope curve. of confident. even will this Given it of these
confidence that a we are we our continuing our As testament stakeholders the future. future, in want reassure to to in the invest to
and pipeline, are gradually second continue restoring and of we other initiatives. programs the quarter stage earlier prioritize to clinical advance We and our during dry retinal near-term our many eye
been investments. never to these has position capital Our support stronger
and to commercial remain progress realities. enterprise core an already completed notes successfully fuels quarter, During and call the strong of This successful we total invest capped financial strengthen R&D systems, clinical our raise fortifies and growth pharmaceutical offering expertise, offense capital they of advance our on becoming proceeds $XXX.X in the net million. infrastructure, convertible raising programs towards us initiatives, and to global our with longer-term expand programs our near support transactions second position flexibility upgrade our our senior our as
As believe believe to we development you the in programs in of XX and which underway. also disclosed stages We clinical ophthalmology, comprehensive be one these of disclosed we pipelines XX consists development know, publicly programs and have are healthy robust the pipeline Epi-On and cadence programs expand coming years. iDose most yet various with a pivotal potential our TR. active infinite, including and are of addressable new product market significantly opportunities clinical programs A in iStent over pipeline number will to launch these support the trials, another
work infinite fully trials, these for already and to Clinical continue the been due iStent to investigators potential closely with and For any mitigate have our COVID-XX FDA clinical disruption. impacts to Epi-On enrolled. we trials
effective. caused the initiatives disruption to implemented in patient follow-up plans, we Although are study believe some ensure we've COVID-XX modest viability has
on believe track respectively. discussed and to are our that XXXX, candidates approval continue FDA late these We XXXX for of product targets previously
shutdown. expectations to For potential FDA been momentum to we enrollment, the that in patient that we COVID-XX analyze where approval XXXX. to are reignite encouraged to treating a the and built patients now iDose, pandemic in continue majority our temporary trends timeline and We're new enrollment the prior of on sites investigator has enrollment pause led focus our reopening for
remain preparations an the potential PRESERFLO in launch Pharmaceuticals glaucoma also the We US ab-externo late-stage of early MicroShunt, management. for surgical Santen commercial for implant
our opportunity this successful ramping following PMA commercial this earlier begun submission in promising announced Santen's quarter. have US We up preparations already
upon or we that received recently FDA we coming to the are iStent announce technologies W. proven commercialize that years, select over receptivity inject iStent addition micro-scale the positive excited inject truly The footprint, card inject to international market the inject excited aim offer launched, two-stent PMA visualization approval inject In intend designed W new to a maintaining markets builds supersede in the these commercial in procedural we W and iStent our to and W Australia. US technology. and for predictability. supplemental next-generation of device and the micro-bypass efficacy upon has enhancements implantation with inject streamline the while already same prospects will this the initial to iStent such commercial to safety stent W the including where product based inject commercialize current been initial for for later feedback benefits about wider designed surgeons delivering optimize stent added iStent in Feature US foundation and trabecular is in established globally Germany flange, year. activities we surgeon iStent We're ophthalmic This iStent launch as commence US
initiatives. that also progress Japan, We In in of iStent approval to standalone of recent later a European growth adds for our this us inject of our commence indication planning broader across position many iStent long-term year. to commercial launch key and access international number inject This in are markets W accomplishments. continued including Australia a regulatory market approval
as extremely milestones on front, I corneal we progress commercial the On and execute strategies. integration pleased with corporate the our health am
to targeting and access, these and key efforts. our with processes program. customers the cross-functional has on they segmentation office in made and considerable our landscape, on Photrexa benefits continue claims team are claims and plans We staff contractual integration deployment, seeing account commercial training ARCH training, With optimize to with expand work reimbursement conjunction market we execute through and of our providers progress payers as end-market
that investigators While markets' potential, we've markets months. integrated with of full receptivity prospects seek of recovery we a the and create business are early the organizations' for glaucoma, disease disrupt and we longer-term vision actions opportunities. the initiatives pandemic thriving paradigms, and in confident fully expanded these These do our In as unique the encouraged actions several novel corneal a going last franchises support clinical therapies the I the patient positioned create unlocking past organization robust am leave taken conventional us and our retinal strong fundamental well with care customer-friendly as remain introduced. commercial strong our treatment outcomes navigate strategic to in over and combined of stages I customers' improve through these and an building summary, the am forward remain to and employees proud and health we've we organization - that leader COVID-XX new
second call turn quarter results, that, I financial with to over the So Joe XXXX will and to our Joe. discuss
